O	0	17	Multidisciplinary
O	18	26	Approach
O	27	29	to
O	30	35	Novel
O	36	45	Therapies
O	46	48	in
O	49	55	Cardio
O	55	56	-
O	56	64	Oncology
O	65	73	Research
O	74	75	(
O	75	84	MANTICORE
O	85	88	101
O	88	89	-
O	89	95	Breast
O	95	96	)
O	96	97	:
O	98	99	A
O	100	110	Randomized
O	111	116	Trial
O	117	120	for
O	121	124	the
O	125	135	Prevention
O	136	138	of
B-condition	139	150	Trastuzumab
I-condition	150	151	-
I-condition	151	161	Associated
I-condition	162	176	Cardiotoxicity
O	176	177	.

O	178	185	Purpose
O	186	189	The
O	190	197	primary
O	198	206	toxicity
O	207	209	of
O	210	221	trastuzumab
O	222	229	therapy
O	230	233	for
O	234	239	human
O	240	249	epidermal
O	250	256	growth
O	257	263	factor
O	264	272	receptor
O	273	274	2
O	274	275	-
O	275	289	overexpressing
O	290	291	(
O	291	295	HER2
O	295	296	-
O	296	304	positive
O	304	305	)
O	306	312	breast
O	313	319	cancer
O	320	322	is
O	323	327	dose
O	327	328	-
O	328	339	independent
O	340	347	cardiac
O	348	359	dysfunction
O	359	360	.

O	361	372	Angiotensin
O	372	373	-
O	373	383	converting
O	384	390	enzyme
O	391	401	inhibitors
O	402	405	and
O	406	407	β
O	407	408	-
O	408	416	blockers
O	417	420	are
O	421	432	recommended
O	433	438	first
O	438	439	-
O	439	443	line
O	444	450	agents
O	451	454	for
O	455	460	heart
O	461	468	failure
O	468	469	.

O	470	472	We
O	473	485	hypothesized
O	486	490	that
O	491	502	angiotensin
O	502	503	-
O	503	513	converting
O	514	520	enzyme
O	521	531	inhibitors
O	532	535	and
O	536	537	β
O	537	538	-
O	538	546	blockers
O	547	552	could
O	553	560	prevent
O	561	572	trastuzumab
O	572	573	-
O	573	580	related
O	581	595	cardiotoxicity
O	595	596	.

O	597	605	Patients
O	606	609	and
O	610	617	Methods
O	618	620	In
O	621	625	this
O	626	632	double
O	632	633	-
O	633	640	blinded
O	640	641	,
O	642	649	placebo
O	649	650	-
O	650	660	controlled
O	661	666	trial
O	666	667	,
B-eligibility	668	676	patients
I-eligibility	677	681	with
I-eligibility	682	686	HER2
I-eligibility	686	687	-
I-eligibility	687	695	positive
I-eligibility	696	701	early
I-eligibility	702	708	breast
I-eligibility	709	715	cancer
O	716	720	were
O	721	729	randomly
O	730	738	assigned
O	739	741	to
O	742	749	receive
O	750	759	treatment
O	760	764	with
B-intervention	765	776	perindopril
I-intervention	776	777	,
I-intervention	778	788	bisoprolol
O	788	789	,
O	790	792	or
B-control	793	800	placebo
O	801	802	(
O	802	803	1
O	803	804	:
O	804	805	1
O	805	806	:
O	806	807	1
O	807	808	)
O	809	812	for
O	813	816	the
O	817	825	duration
O	826	828	of
O	829	840	trastuzumab
O	841	849	adjuvant
O	850	857	therapy
O	857	858	.

O	859	867	Patients
O	868	877	underwent
O	878	885	cardiac
O	886	894	magnetic
O	895	904	resonance
O	905	912	imaging
O	913	915	at
O	916	924	baseline
O	925	928	and
O	929	933	post
O	933	934	-
O	934	939	cycle
O	940	942	17
O	943	946	for
O	947	950	the
O	951	964	determination
O	965	967	of
O	968	972	left
O	973	984	ventricular
O	985	992	volumes
O	993	996	and
O	997	1001	left
O	1002	1013	ventricular
O	1014	1022	ejection
O	1023	1031	fraction
O	1032	1033	(
O	1033	1037	LVEF
O	1037	1038	)
O	1038	1039	.

O	1040	1054	Cardiotoxicity
O	1055	1058	was
O	1059	1068	evaluated
O	1069	1071	as
O	1072	1075	the
O	1076	1082	change
O	1083	1085	in
O	1086	1093	indexed
O	1094	1098	left
O	1099	1110	ventricular
O	1111	1114	end
O	1115	1124	diastolic
O	1125	1131	volume
O	1132	1135	and
O	1136	1140	LVEF
O	1140	1141	.

O	1142	1149	Results
B-intervention-participants	1150	1156	Thirty
I-intervention-participants	1156	1157	-
I-intervention-participants	1157	1162	three
O	1163	1171	patients
O	1172	1180	received
O	1181	1192	perindopril
O	1192	1193	,
B-intervention-participants	1194	1196	31
O	1197	1205	received
O	1206	1216	bisoprolol
O	1216	1217	,
O	1218	1221	and
B-control-participants	1222	1224	30
O	1225	1233	received
O	1234	1241	placebo
O	1241	1242	.

O	1243	1251	Baseline
O	1252	1263	demographic
O	1263	1264	,
O	1265	1271	cancer
O	1271	1272	,
O	1273	1276	and
O	1277	1291	cardiovascular
O	1292	1300	profiles
O	1301	1305	were
O	1306	1313	similar
O	1314	1321	between
O	1322	1328	groups
O	1328	1329	.

O	1330	1335	Study
O	1336	1341	drugs
O	1342	1346	were
O	1347	1351	well
O	1352	1361	tolerated
O	1362	1366	with
B-outcome	1367	1369	no
I-outcome	1370	1377	serious
I-outcome	1378	1385	adverse
I-outcome	1386	1392	events
O	1392	1393	.

O	1394	1399	After
O	1400	1402	17
O	1403	1409	cycles
O	1410	1412	of
O	1413	1424	trastuzumab
O	1424	1425	,
O	1426	1433	indexed
B-outcome	1434	1438	left
I-outcome	1439	1450	ventricular
I-outcome	1451	1454	end
I-outcome	1455	1464	diastolic
I-outcome	1465	1471	volume
O	1472	1481	increased
O	1482	1484	in
O	1485	1493	patients
O	1494	1501	treated
O	1502	1506	with
O	1507	1518	perindopril
O	1519	1520	(
B-iv-cont-mean	1520	1521	+
I-iv-cont-mean	1521	1522	7
O	1523	1524	±
B-iv-cont-sd	1525	1527	14
I-iv-cont-sd	1528	1530	mL
I-iv-cont-sd	1530	1531	/
I-iv-cont-sd	1531	1533	m2
O	1533	1534	)
O	1534	1535	,
O	1536	1546	bisoprolol
O	1547	1548	(
B-iv-cont-mean	1548	1549	+
I-iv-cont-mean	1549	1550	8
I-iv-cont-mean	1551	1553	mL
O	1554	1555	±
B-iv-cont-sd	1556	1557	9
I-iv-cont-sd	1558	1560	mL
I-iv-cont-sd	1560	1561	/
I-iv-cont-sd	1561	1563	m2
O	1563	1564	)
O	1564	1565	,
O	1566	1569	and
O	1570	1577	placebo
O	1578	1579	(
B-cv-cont-mean	1579	1580	+
I-cv-cont-mean	1580	1581	4
O	1582	1583	±
B-cv-cont-sd	1584	1586	11
I-cv-cont-sd	1587	1589	mL
I-cv-cont-sd	1589	1590	/
I-cv-cont-sd	1590	1592	m2
O	1592	1593	;
O	1594	1595	P
O	1596	1597	=
O	1598	1599	.
O	1599	1601	36
O	1601	1602	)
O	1602	1603	.

O	1604	1606	In
O	1607	1616	secondary
O	1617	1625	analyses
O	1625	1626	,
O	1627	1638	trastuzumab
O	1638	1639	-
O	1639	1647	mediated
B-outcome	1648	1655	decline
I-outcome	1656	1658	in
I-outcome	1659	1663	LVEF
O	1664	1667	was
O	1668	1678	attenuated
O	1679	1681	in
O	1682	1692	bisoprolol
O	1692	1693	-
O	1693	1700	treated
O	1701	1709	patients
O	1710	1711	(
B-iv-cont-mean	1711	1712	-
I-iv-cont-mean	1712	1713	1
O	1714	1715	±
B-iv-cont-sd	1716	1717	5
I-iv-cont-sd	1717	1718	%
O	1718	1719	)
O	1720	1728	relative
O	1729	1731	to
O	1732	1735	the
O	1736	1747	perindopril
O	1748	1749	(
B-iv-cont-mean	1749	1750	-
I-iv-cont-mean	1750	1751	3
O	1752	1753	±
B-iv-cont-sd	1754	1755	4
I-iv-cont-sd	1755	1756	%
O	1756	1757	)
O	1758	1761	and
O	1762	1769	placebo
O	1770	1771	(
B-cv-cont-mean	1771	1772	-
I-cv-cont-mean	1772	1773	5
O	1774	1775	±
B-cv-cont-sd	1776	1777	5
I-cv-cont-sd	1777	1778	%
O	1778	1779	)
O	1780	1786	groups
O	1787	1788	(
O	1789	1790	P
O	1791	1792	=
O	1793	1794	.
O	1794	1797	001
O	1797	1798	)
O	1798	1799	.

O	1800	1811	Perindopril
O	1812	1815	and
O	1816	1826	bisoprolol
O	1827	1830	use
O	1831	1835	were
O	1836	1847	independent
O	1848	1858	predictors
O	1859	1861	of
O	1862	1872	maintained
O	1873	1877	LVEF
O	1878	1880	on
O	1881	1894	multivariable
O	1895	1903	analysis
O	1903	1904	.

O	1905	1915	Conclusion
O	1916	1927	Perindopril
O	1928	1931	and
O	1932	1942	bisoprolol
O	1943	1947	were
O	1948	1952	well
O	1953	1962	tolerated
O	1963	1965	in
O	1966	1974	patients
O	1975	1979	with
O	1980	1984	HER2
O	1984	1985	-
O	1985	1993	positive
O	1994	1999	early
O	2000	2006	breast
O	2007	2013	cancer
O	2014	2017	who
O	2018	2026	received
O	2027	2038	trastuzumab
O	2039	2042	and
O	2043	2052	protected
O	2053	2060	against
O	2061	2067	cancer
O	2068	2075	therapy
O	2075	2076	-
O	2076	2083	related
O	2084	2092	declines
O	2093	2095	in
O	2096	2100	LVEF
O	2100	2101	;
O	2102	2109	however
O	2109	2110	,
O	2111	2122	trastuzumab
O	2122	2123	-
O	2123	2131	mediated
B-outcome-Measure	2132	2136	left
I-outcome-Measure	2137	2148	ventricular
I-outcome-Measure	2149	2159	remodeling
O	2159	2160	-
O	2160	2163	the
O	2164	2171	primary
O	2172	2179	outcome
O	2179	2180	-
O	2180	2183	was
O	2184	2187	not
O	2188	2197	prevented
O	2198	2200	by
O	2201	2206	these
O	2207	2224	pharmacotherapies
O	2224	2225	.
